Exploring the interplay between tumor burden and liquid biopsy longitudinal evaluation in hormone receptor-positive, HER2-negative metastatic breast cancer (MBC)

被引：0

作者：

Mazzeo, R. ^{[1
]}

Bortot, L. ^{[1
]}

Michelotti, A. ^{[1
]}

Buriolla, S. ^{[1
]}

Palmero, L. ^{[1
]}

Franzoni, A. ^{[2
]}

Bertoli, E. ^{[1
]}

Targato, G. ^{[1
]}

Allegri, L. ^{[2
]}

Da Ros, L. ^{[3
]}

Alberti, M. ^{[1
]}

Di Nardo, P. ^{[3
]}

Bonotto, M. ^{[4
]}

Sodde, S. ^{[5
]}

Belletti, B. ^{[6
]}

Spazzapan, S. ^{[3
]}

Baldassarre, G. ^{[6
]}

Damante, G. ^{[2
]}

Gerratana, L. ^{[1
]}

Puglisi, F. ^{[3
]}

机构：

[1] Univ Udine, Dept Med DAME, Udine, Italy

[2] Azienda Sanit Univ Friuli Cent ASUFC Udine, Inst Human Genet, Udine, Italy

[3] Ctr Riferimento Oncol CRO IRCCS, Dept Med Oncol, Aviano, Italy

[4] Azienda Sanit Univ Friuli Cent ASUFC Udine, Med Oncol, Udine, Italy

[5] Ctr Riferimento Oncol CRO IRCCS, Clin Trial Off, Aviano, Italy

[6] Ctr Riferimento Oncol CRO IRCCS, Mol Oncol Unit, Aviano, Italy

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.576

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

293P

引用

页码：S492 / S493

页数：2

共 50 条

[1] Liquid biopsy for baseline evaluation of tumor burden in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A proof of principle study.
Mazzeo, Roberta
Bortot, Lucia
Michelotti, Anna
Buriolla, Silvia
Palmero, Lorenza
Franzoni, Alessandra
Bertoli, Elisa
Targato, Giada
Allegri, Lorenzo
Da Ros, Lucia
Alberti, Martina
Di Nardo, Paola
Bonotto, Marta
Sodde, Sara
Belletti, Barbara
Spazzapan, Simon
Baldassarre, Gustavo
Damante, Giuseppe
Gerratana, Lorenzo
Puglisi, Fabio
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
Matutino, A.
Joy, A. A.
Brezden-Masley, C.
Chia, S.
Verma, S.
CURRENT ONCOLOGY, 2018, 25 : S131 - S141
[3] Immunotherapy for hormone receptor-positive HER2-negative breast cancer
Cardoso, Fatima
Hirshfield, Kim M.
Kraynyak, Kimberly A.
Tryfonidis, Konstantinos
Bardia, Aditya
NPJ BREAST CANCER, 2024, 10 (01)
[4] Evolving treatment patterns in hormone receptor-positive, HER2-negative metastatic breast cancer
Lankford, M. L.
Britton, S. L.
Buettner, A. D.
Scharf, M.
Tiscione, B.
Willey, J. P.
Mahtani, R. L.
CANCER RESEARCH, 2019, 79 (04)
[5] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
Cantini, Luca
Trapani, Dario
Guidi, Lorenzo
Bielo, Luca Boscolo
Scafetta, Roberta
Koziej, Marcin
Vidal, Laura
Saini, Kamal S.
Curigliano, Giuseppe
CANCER TREATMENT REVIEWS, 2024, 123
[6] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
K. Almstedt
S. Mendoza
M. Otto
M. J. Battista
J. Steetskamp
A. S. Heimes
S. Krajnak
A. Poplawski
A. Gerhold-Ay
A. Hasenburg
C. Denkert
M. Schmidt
Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
[7] Molecular classification of hormone receptor-positive HER2-negative breast cancer
Jin, Xi
Zhou, Yi-Fan
Ma, Ding
Zhao, Shen
Lin, Cai-Jin
Xiao, Yi
Fu, Tong
Liu, Cheng-Lin
Chen, Yi-Yu
Xiao, Wen-Xuan
Liu, Ya-Qing
Chen, Qing-Wang
Yu, Ying
Shi, Le-Ming
Shi, Jin-Xiu
Huang, Wei
Robertson, John F. R.
Jiang, Yi-Zhou
Shao, Zhi-Ming
NATURE GENETICS, 2023, 55 (10) : 1696 - +
[8] Management of hormone receptor-positive, HER2-negative early breast cancer
Walsh, Elaine M.
Smith, Karen L.
Stearns, Vered
SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
[9] Molecular classification of hormone receptor-positive HER2-negative breast cancer
Xi Jin
Yi-Fan Zhou
Ding Ma
Shen Zhao
Cai-Jin Lin
Yi Xiao
Tong Fu
Cheng-Lin Liu
Yi-Yu Chen
Wen-Xuan Xiao
Ya-Qing Liu
Qing-Wang Chen
Ying Yu
Le-Ming Shi
Jin-Xiu Shi
Wei Huang
John F. R. Robertson
Yi-Zhou Jiang
Zhi-Ming Shao
Nature Genetics, 2023, 55 : 1696 - 1708
[10] Alternative Palbociclib Dosing Schedules for Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer
Go, Makiko
Kimura, Michio
Yamada, Shiori
Kamei, Keitaro
Noguchi, Yoshinori
Usami, Eiseki
Yoshimura, Tomoaki
ONCOLOGY, 2024,

← 1 2 3 4 5 →